Ix Biopharma
Ix Biopharma Ltd, headquartered in Singapore (SG), is a pioneering biopharmaceutical company specialising in the development of innovative drug delivery systems. Founded in 2008, Ix Biopharma has made significant strides in the industry, particularly with its proprietary WaferiX™ technology, which enhances the delivery of therapeutics through sublingual administration. The company focuses on pain management and other therapeutic areas, offering unique products that provide rapid onset and improved bioavailability. With a strong commitment to research and development, Ix Biopharma has positioned itself as a leader in the biopharmaceutical sector, achieving notable milestones in product development and regulatory approvals. Its dedication to advancing patient care through innovative solutions underscores its reputation as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Ix Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ix Biopharma's score of 12 is lower than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ix Biopharma's reported carbon emissions
In 2023, Ix Biopharma reported approximately 937,000 kg CO2e in Scope 2 emissions, a slight increase from about 714,000 kg CO2e in 2022. The emissions for 2024 are projected to be around 949,000 kg CO2e, indicating a continued focus on monitoring their carbon footprint. Despite these figures, there are currently no specific reduction targets or initiatives disclosed by Ix Biopharma. The company has not committed to any science-based targets or climate pledges, which places them in a challenging position within the biopharmaceutical industry, where many peers are actively pursuing aggressive climate action strategies. Overall, while Ix Biopharma is tracking its emissions, the absence of defined reduction goals highlights an opportunity for the company to enhance its climate commitments and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | 997,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ix Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
